soul trial oral semaglutide cardiovascular outcomes Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo Cardiovascular outcomes of semaglutide and

The $63-billion GLP-1 agonist industry is forecast to triple in the coming decade, so it's no surprise that pharmaceuticals companies of all sizes are scrambling to get in on the action

Ghosh A, et al

Your provider will review your symptoms, health history, lifestyle, and wellness goals before recommending a treatment plan

GLP-1 Use Among Seniors Despite the potential of GLP-1 medications to improve health outcomes in older adults, their use remains low

However, the lack of folate in the diet, or the lack of folic acid supplementation, is directly correlated to neural tube defects occurring during fetal development